New combo strategy aims to speed up UC remission without sacrificing safety

NCT ID NCT06095596

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a sequential treatment for moderate to severe ulcerative colitis. First, patients take upadacitinib (a fast-acting pill) along with vedolizumab (a slow but safe infusion) for 8 weeks to quickly reduce inflammation. Then, they continue with vedolizumab alone for long-term control. The goal is to combine the speed of upadacitinib with the safety of vedolizumab. The trial will enroll 334 adults and measure how many achieve endoscopic remission at week 8.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Vedolizumab and upadacitinib
What this could lead to
If successful, this sequential approach could offer a way to quickly bring ulcerative colitis under control and then maintain remission safely with a single drug.
What could go wrong
This is an early-stage study with no phase designation, so results are uncertain. Upadacitinib carries risks like infection and blood clots, and the combination may not prove better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS (UC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • the Sixth Affiliated Hospital of Sun Yat-Sen University

    RECRUITING

    Guangzhou, Guangdong, 501655, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.